Nuevolution AB (publ) announced that the company will present data from its IL-17A program at four scientific and industry focused conferences during fourth quarter 2018. The presentations will cover the journey from initial identification of attractive (series of) drug-like molecules from the screening of the world large collection of test molecules using Nuevolutions unique Chemetics drug discovery platform technology through the optimization and improvement process in this disease relevant and attractive IL-17A program. Unique first in class opportunity: IL-17A has presented itself as a very challenging disease protein to inhibit (block) with small molecules and therefore represent a unique, first-in-class, high value opportunity for new topical (e.g. cream or gel) or oral (e.g. tablet) treatment effectively inhibiting IL-17A function. IL-17A is the key cell signalling molecule responsible for driving multiple inflammatory diseases such as psoriasis, psoriatic arthritis, ankylosing spondylitis (type of arthritis in the lower back) and is considered a major contributing factor in diseases such as inflammatory bowel disease (inflammation in the intestines) and multiple sclerosis. Significant potential: Current IL-17A blockade treatment is only offered through use of very expensive injectable antibodies. The optimization efforts focus on finalizing data for initially a topical use (treatment on the skin) of its IL-17A blockers as well as seeking a potential systemic (tablet-based) formulation with the ambition of achieving a first-in-class development program. The current annual sales for major inflammatory diseases, i.e. psoriasis, psoriatic arthritis and ankylosing spondylitis amount to USD 16 billion. The potential topical and systemic market for an effective IL 17A blocker is currently estimated to potentially reach USD 27 billion (2024) in annual sales (Global Data, 2016).